British Journal of Dermatology

Article	Citations
银屑病皮肤细胞中的小分子 RNA 促进炎症发生	330
Correction	230
P91: Cutaneous adverse events of immune check point inhibitors nivolumab, pembrolizumab and atezolizumab: a multicentric study	180
Adding up the desmosomal genes causing syndromes with hair and skin involvement: identification of TUFT1 by state-of-the-art whole-genome sequencing	124
Comparison of incidence, causes and prognosis of adult and paediatric epidermal necrolysis: a French population-based study	112
Atypical melanocytes of an atypical Spitz tumour observed with optical super-high magnification dermoscopy	99
Seeking new topical therapies in psoriasis	98
How to score the impact of treatment on cutaneous neurofibromas in clinical trials	89
The association of anxiety with granuloma annulare: a case–control study of the National Institutes of Health ‘All of Us’ research programme	84
Delusional infestation – do not be scared!	84
O11 The human discs large protein (Dlg1) controls connexin 43 (Cx43) plasma membrane localization and gap junctional communication in keratinocytes	79
O06 Exploring host–microbiome–immune interactions using singular and multispecies inoculations in optimized 3D skin models	78
Interactive effect of genetic and environmental risk factors on psoriasis: current evidence and future directives	77
Editor's Choice – John Ingram – Sep 2023	75
一项在一家大型教学医院进行的 5 年皮肤附属器肿瘤研究, 对关联基因诊断提供了启示	74
空气污染会导致皮肤颜色变深	72
对化疗所致脱发的更深入了解	72
P100: Efficacy of current treatments under study in patients with alopecia areata	69
Recognizing psoriasis in children and adolescents: the DIPSOC study	67
BH13: Scarring alopecia affecting a congenital melanocytic naevus in a patient with frontal fibrosing alopecia	66
P15: Twenty years of the UK Dermatology Clinical Trials Network: past, present and future	64
CPC11: Bromoderma in a patient with chronic obstructive pulmonary disease	64
P57: New order: redesigning referral pathways to improve access for patients from dermatology outpatient waiting lists	59
开展健康宣传活动，禁售日光浴床，以减少皮肤癌: 合理利用医疗预算	58
BH09: Frontal fibrosing alopecia in men: is it any different?	58

H10: A Sweet diagnosis to make: the history of Robert Douglas Sweet and acute febrile neutrophilic dermatosis	58
P52: Opportunities for implementing a patient‐initiated follow‐up pathway in patients with psoriasis completing narrowband ultraviolet B phototherapy	57
Possible new oral treatment for hidradenitis suppurativa	56
Issue Information	56
DP27: Maculopapular cutaneous mastocytosis mimicking seborrhoeic folliculitis	54
皮肤红斑狼疮治疗指南	53
P53: Office 365: Microsoft Lists as a tool for a secure online second‐line/systemic drug database	53
DP12: An 11‐year mystery	52
Higher proportion of cellulitis in severe lymphoedema	52
Integrating artificial intelligence into skin cancer pathways: the opportunities and obstacles	51
Greater understanding about differences in the long-term course of eczema and their risk factors in children	49
561 - Dupilumab treatment reduces signs in patients with atopic hand and foot dermatitis: results from a phase 3, randomized, double-blind, placebo-controlled trial	48
520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin	48
Methotrexate and ciclosporin improve skin biomarkers in paediatric atopic dermatitis: results from the TREatment of severe Atopic eczema Trial	47
A current need for the use of improved and standardized outcome measures by clinical studies of pemphigus	47
Occupational skin cancer: measurements of ultraviolet radiation exposure bring knowledge for prevention	46
A guide to using the core outcome set for eczema	45
GD07: The use of the Dermatology Life Quality Index suite of patient‐reported outcome measures in neglected tropical diseases of the skin: a systematic review	44
Risankizumab versus apremilast in the era of skin clearance	44
Editor's Choice – John Ingram – December 2023	44
Incidence, mortality and survival in people with Merkel cell carcinoma: a systematic review	43
Mosaic EGFR exon 20 in-frame insertion pathogenic variants are associated with papular epidermal naevus with ‘skyline’ basal cell layer (PENS)	43
BT25: Dermatology and the metaverse: what’s on the horizon?	43
‘Substantial clinical benefit’ and ‘substantial clinical worsening’ cutoff of Vitiligo Impact Scale (VIS)-22 change scores	43
O22 Unravelling the pathophysiology of KLICK syndrome to identify therapeutically targetable pathways	43
Corrigendum	43
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa	42
Multicentre phase II trial of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab in Japanese advanced melanoma patients: immune resistance remains one of the major efforts in melanoma	41
Missing melanomas in England during the COVID-19 pandemic: 2485 fewer melanoma diagnoses in 2020 than in 2019	41
Dupilumab improves patient-reported symptoms and health-related quality of life in children aged 6–11 years with severe atopic dermatitis	41
UK trends in work-related contact dermatitis caused by nickel, chromium and cobalt	40
BH09 Mycophenolate mofetil in the management of lichen planus pigmentosus in a woman with frontal fibrosing alopecia	39
H19 Not only a finder of ‘solutions’: Max Jessner, Holocaust survivor and discoverer of Jessner–Kanof lymphocytic infiltrate	38
H20 Sarcoptes scabiei: to solve the current crisis, hunt for clues in our past	38
BH13 Current wig prescribing practices and financial evaluation in a National Health Service foundation trust: lessons learnt and future challenges	38
PA12 Fats and figures: how abnormal lipids unravel the truth	38
H06 The changing face of skin disease in warfare: from World War I to modern times	37
Poster presentationsBT15 Ethical implications of artificial intelligence in dermatology: use-case analysis of skin cancer diagnostic smartphone apps	37
Poster presentationsPA10 Hidradenitis suppurativa and trisomy 21: a case series	37
O05 Risk of keratinocyte carcinomas in patients with psoriasis treated with biologic therapy: analysis from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR),	36
DS24 Is surgery the best management for keratoacanthoma centrifugum marginatum?	36
SG08 The phenotypic spectrum of MBTPS2 mutations: two illustrative cases	36
P093 Bespoke omalizumab prescribing in chronic spontaneous urticaria	36
DS23 Evaluation of American Joint Committee on Cancer and alternative tumour classification systems for primary penile squamous cell carcinoma	36
Mainstreaming genetic testing in dermatology in the UK	35
Uncovering the genetic architecture of hidradenitis suppurativa	35
Gain-of-function variant in NNT causes premature diffuse familial sebaceous hyperplasia	35
The role of clinicians in dermatology industry innovation: a qualitative study	34
Avelumab plus cetuximab in advanced cutaneous squamous cell carcinoma: a strategy to overcome resistance to PD-1 blockade	34
Neutrophil infiltration in allergic contact dermatitis to nickel	34

From connective tissue builders to cellular architects: the journey of the skin fibroblast	34
Sexual and gender minority inclusivity in hidradenitis suppurativa patient-reported outcome measures	33
Correction to: Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded c	33
Navigating the challenges in clinical trials for bullous pemphigoid and pemphigus: learnings from the clinical trial graveyard and an international expert survey	33
Multi-Harmonic Imaging-Based Automated Recognition of Cutaneous T-Cell Lymphoma	33
Proliferative actinic keratoses are associated with adverse clinical outcomes relative to actinic keratoses without a proliferative growth pattern	33
Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: an EORTC CLTG study	33
Burden of atopic dermatitis in paediatric patients: an international cross-sectional study	33
Newborn genome screening (the Generation Study): the advent of presymptomatic diagnosis for genodermatoses	33
Prurigo nodularis: disease burden, clinical features and approach to management	33
Mechanistic in vivo studies of secondary skin-to-skin peanut allergen transfer to determine the impact of hand washing in reducing the risk of cutaneous sensitization	32
CD03 Contact sensitization to shellac: a possible marker of fragrance allergy	32
Can the effects of the COVID-19 pandemic provide insights into the impact of melanoma underdiagnosis and delayed care?	32
P068 A history of mycosis fungoides: from Alibert to mogamulizumab	32
010 Enhanced outcome prediction in cutaneous squamous cell carcinoma using deep-learning and computational histopathology (cSCCnet)	31
P13 A rare case of Sjögren syndrome in a White woman with Kikuchi–Fujimoto disease	31
P50 Exploring unmet needs and attitudes to skin self-examination in melanoma survivors: EUNASS study	31
SG10 (P058) The epidemiology of epidermolysis bullosa in England, 1997–2024: a retrospective national cohort study	30
PA37 A retrospective review of the impact of virtual reality headsets in paediatric skin surgery	30
730 - Patient opinions on healthcare provider interactions and current treatment satisfaction in adults with atopic dermatitis by race and ethnicity	30
DP22 Cutaneous lymphoid hyperplasia: clinicopathological correlation and a therapeutic option	30
CPC02 Delayed widespread lichenoid drug reaction with radioisotopic response in a patient treated with nivolumab	29
P74 Guselkumab clinical super-response is associated with faster normalization of blood and skin pathology: data from the Phase 3b GUIDE trial	28
PA24 Abnormal interferon signature in a patient with chilblain lupus	28
P67 Overall lifetime risk for alopecia areata is 2.1% and is higher in women, non-White ethnic groups and the most deprived: a UK population-based cohort study	28
P068 Oral tofacitinib in comparison with dexamethasone oral mini-pulse therapy for the treatment of active nonsegmental vitiligo: a randomized controlled trial	28
BH08 Unprovoked pulmonary emboli in a patient with alopecia areata treated with ritlecitinib: a case report	28
677 - Establishing a patient-centered definition of atopic dermatitis flare: insights from a modified eDelphi study	27
DP21 Thymoma and the skin: manifestations of multiorgan autoimmunity	27
352 Efficacy and safety of abrocitinib in Chinese patients with moderate-to-severe atopic dermatitis: a post-hoc analysis of the JADE REGIMEN phase 3 trial	27
BI26 Treatment-induced scleroderma in a patient with metastatic melanoma	27
BH18 A rare case of nail sarcoidosis presenting as an ulcerated nail tumour in a Afro-Caribbean patient	27
603 - Ruxolitinib cream 1.5% twice daily for the treatment of extensive atopic dermatitis in children aged 2–11 years: 52 week results from a maximum-use trial	27
335 Improvement in sleep quality, anxiety and depression in adults with moderate-to-severe atopic dermatitis with dupilumab treatment	27
SG02 Transdermal testosterone improves lower-extremity ulceration in a young man with newly diagnosed Klinefelter syndrome (47 XXY)	27
691 - Understanding patient and physician preferences when choosing between biologic and oral systemic treatment options for moderate-to-severe atopic dermatitis: a discrete choice experiment	26
705 - Patient preferences for atopic dermatitis treatment profiles: results from a discrete choice experiment	26
P020 A rare phenomenon in a rare disease: reverse Koebner phenomenon in cutaneous Rosai–Dorfman disease	26
643 - Effectiveness and safety of upadacitinib in adolescent and adult patients with atopic dermatitis: an analysis of short-term (week 8-20) data from a real-world multicenter retrospective review	26
673 - Efficacy of nemolizumab in different subgroups of patients with prurigo nodularis in two randomized, placebo-controlled phase 3 trials	26
O02 Skin cancer service disparities across England: what data can tell us about skin cancer diagnosis, referral pathways and treatment received in different NHS trusts	26
P19 The association between psoriatic disease severity and adherence to the Mediterranean diet: a systematic review of observational studies	26
P099 Spesolimab use in effective treatment of generalized pustular psoriasis: a case report	25
BT12 A comparison of outcomes and cost-effectiveness in a teledermatology vs. a standard face-to-face 2-week wait UK model	25
BT06 (P163) Implementation of a novel direct-to-patient inflammatory teledermatology service	25
005 Association between prescription drugs and vaccines commonly prescribed to older people and bullous pemphigoid: a UK population-based study	24
641 - Pooled efficacy, patient-reported outcomes, and safety of roflumilast cream 0.15% from the INTEGUMENT-1 and INTEGUMENT-2 phase 3 trials of adults and children with atopic dermatitis	24
P79 A multidisciplinary expert consensus on the assessment of and support for mental health in children and young people living with skin conditions	24
H17 Traditional medicine: a warts-and-all tale	24
BI08 Defining the burden of mucocutaneous disease in organ transplant recipients living with HIV: the Mucocutaneous disorders in Organ Transplant recipients living with HIV study	24
H15 A treatment for leprosy developed on the edge of Europe: Vincent Barry (1908–1975)	24
BH10 Nailing the diagnosis	24
How do dermatologists’ personal models inform a patient‐centred approach to management: a qualitative study using the example of prescribing a new treatment (Apremilast)*	23
Clinical practices and educational interests of dermatologists in Caribbean countries	23
The future of patient-reported outcome measurement in hyperhidrosis lies in thoughtful, evidence-based implementation	23
Long-term drug survival of adalimumab, infliximab, secukinumab and ustekinumab in hidradenitis suppurativa: a Danish nationwide cohort study	23
519 - Efficacy of prolonged ruxolitinib cream treatment for vitiligo among patients with limited or no initial response at 6 months	23
ISCL/EORTC-CLTG/USCLC recommendations for the diagnosis, staging and treatment of early-stage paediatric mycosis fungoides: a modified Delphi consensus. Part one: diagnosis and staging	23
Real-world data on the effectiveness, safety and drug survival of dupilumab: an analysis from the TREATgermany registry	23
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3 years of treatment in randomized phase III trials	23
DP10: A case of reactive angioendotheliomatosis with resolution following improved glycaemic control	23
Expanding the SLURP1 disease spectrum: from Mal de Meleda to palmoplantar keratoderma/progressive symmetric erythrokeratoderma	23
Consensus on the clinical management of chronic radiation dermatitis and radiation fibrosis: a Delphi survey	22
COVID-19 vaccines and skin manifestations	22
Direct inhibition precedes p38 mitogen activated protein kinase-mediated uncoupling in desmosomes to reduce desmoglein 3 adhesion by pemphigus autoantibodies	22
Eligibility criteria for programmed death receptor 1 inhibitors vs. real‐world advice: a retrospective analysis of 69 patients with advanced cutaneous squamous cell carcinoma of the head and neck	22
Pathways to progress: DUSP1-associated palmoplantar keratoderma in the era of precision dermatology	22
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa	22
Waning humoral and cellular immunity after COVID-19 vaccination in patients with psoriasis treated with methotrexate and biologics: a cohort study	22
Can brepocitinib be formulated into an effective topical therapy to treat mild-to-moderate chronic plaque psoriasis?	21
Trichostasis spinulosa	21
The Venous Garland of Sahli	21
DS17 Two cases of traumatic pseudoaneurysm of the superficial temporal artery	21
Sensitive and specific assay for the serological diagnosis of anti-p200 pemphigoid based on the recombinant laminin β4 subunit	21
Evaluating the role of histopathology in diagnosing pyoderma gangrenosum using Delphi and PARACELSUS criteria: a multicentre, retrospective cohort study	21
514 - Tapinarof cream 1% once daily: significant efficacy in the treatment of atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age	21
Validation of a microRNA liquid biopsy assay for diagnosis and risk stratification of invasive cutaneous melanoma	21
Living with vulval lichen sclerosus: a qualitative interview study	20
Efficacy and safety of pumecitinib 3% gel in treating mild-to-moderate atopic dermatitis: a multicentre randomized double-blind parallel placebo-controlled phase IIb clinical trial	20
Hidradenitis suppurativa: BJD state-of-the-art review series	20

Lived experiences of patients with hidradenitis suppurativa-related pain	20
Genetic basis of a novel rare dominant form of palmoplantar keratoderma	20
Body site-specific associations between human skin microbiome composition and psychological wellbeing	20
Successful treatment of severe subcorneal pustular dermatosis with the 308-nm ultraviolet B excimer laser	20
P17 Pseudomonas infection causing acute painful flexural exacerbation in a child with IFAP syndrome	20
Greater understanding about a rare inherited skin disorder from a study of NLRP1 in two sisters with different severity of disease	20
The relative contribution of the decreasing trend in tumour thickness to the 2010s increase in net survival from cutaneous malignant melanoma in Italy: a population‐based investigation*	20
Correction to: Comment on ‘Treatment of moderate-to-severe alopecia areata in preadolescent children with baricitinib’: authors’ reply	20
Parent and child experiences of skin conditions and views on mindfulness-based support	20
A review of genetic hair disorders	20
P33 Investigating the utility and exploring biological targets of micro-wound healing compounds in 2D and 3D skin models	20
BG12: Cicatricial junctional epidermolysis bullosa: a forgotten subtype	19
DS24: Clinical outcomes of cutaneous squamous cell carcinomas treated with Mohs micrographic surgery	19
Creating the Scale of Alopecia Areata Distress to measure a wide range of negative emotional, social and relationship disease consequences in adults	19
The antidiabetic medicine metformin has beneficial effects in hidradenitis suppurativa	19
Safety of long‐term treatment with risankizumab in patients with moderate‐to‐severe plaque psoriasis	19
H12: Campbell De Morgan: doctor, scientist, polymath	19
P40: Histopathological features of orofacial granulomatosis with and without underlying gut Crohn disease	19
我们如何评估前额纤维化性脱发的严重程度和治疗?	19
BG02 (P35): Alterations of forces applied under the feet in patients with epidermolysis bullosa simplex during gait	19
PA02 (P28): Prediction of FLG genotype using human and computer‐aided phenotype extraction with random forest machine learning	19
便于充分了解炎症后色素沉着的模型	19
P34: Exploring anaemia in hidradenitis suppurativa: a comparative study and proposal of a clinical pathway	18
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa	18
Patient experiences of living with vulval lichen sclerosus	18
Insights into the biological differences in hair follicles of men with androgenetic alopecia	18
PD15 Ultraviolet overexposure in solar urticaria: beyond the rash	18
Adcitmer ® 是 Merkel 细胞癌的潜在治疗方法	18
P55: Post‐COVID analysis of 2‐week wait face‐to‐face activity and the potential for a teledermatology service	18
CD03: Practical use of a limonene and linalool series	18
A clinical trial in children and young people with severe eczema comparing methotrexate with ciclosporin	18
DS05 Overtreatment of skin cancer: how can we ensure those treated for basal cell carcinoma receive more benefit than harm?	18
Review of different staging systems for cutaneous squamous cell carcinoma	18
转移性黑色素瘤免疫治疗后患者恢复生活的经验	18
Varied skin reactions after COVID-19 vaccination	18
P100 Critically appraised topic: is dupilumab a cause or a treatment for alopecia areata? A case series and literature review to guide discussions in clinical practice	18
体重在 90 公斤或以上的银屑病患者获益于更为频繁的苏金单抗给药	18
698 - Impact of amlitelimab (an anti-OX40 ligand antibody) on clinical outcome assessments for atopic dermatitis: results from the 52-week STREAM-AD phase 2b study in adults with moderate-to-severe at	17
BH16 Nail changes as indicators of systemic disease: a systematic review of correlations and diagnostic outcomes	17
PA32 Terra firma-forme dermatosis in siblings	17
PS06 Mindfulness-based stress reduction alleviates flushing and negative emotions in rosacea: an exploratory study	17
‘Quantity does not make quality’: when is there a case for repeating a network meta‐analysis?	17
DS15 Comparing the costs of monitoring vs. excision of an indeterminate naevus	17
PD05 Chronic actinic dermatitis: a multicentre evaluation	17
309 Tralokinumab demonstrated a consistent safety profile with up to 42 months of treatment in moderate-to-severe atopic dermatitis: including adverse events of special interest	17
CPC07 Lines of evidence: unravelling a case of blaschkoid Darier disease	17
P088 Physician-assessed effectiveness, patient-reported outcomes, and safety in adult and adolescent patients with atopic dermatitis treated with dupilumab: real-world insights 1 year into the GLOBOST	17
P101 Janus kinase inhibitors in palmoplantar pustulosis: a systematic review and meta-analysis of comorbidity burden to inform a feasibility trial’s design (JAKPPPOT)	17
BI24 Cutaneous pseudolymphoma secondary to pembrolizumab	17
DS28 In search of salivation? Management of parotid duct injury following Mohs micrographic surgery	17
DS13 (P141) Biodegradable temporizing matrix: a first for dermatological surgery and a valuable reconstructive adjunct	17
Editor's Choice – John Ingram – March 2024	17
Focusing on antigen-specific T cells	17
649 - Safety of tralokinumab for the treatment of atopic dermatitis in patients with up to 4.5 years of treatment: an updated integrated analysis of eight clinical trials	16
FC16 Blood mass cytometry reveals Type 1 cytokine expression in blood of patients with paradoxical eczema secondary to biologics for psoriasis	16
DE04 Large-scale virtual dermatology teaching for internal medical trainees across the UK	16
P111 An AI-assisted similarity search engine for enhanced psoriasis case identification and patient engagement	16
BH03 Lipoedematous scalp occurring in two female siblings: further evidence of a genetic role?	16
326 Dupilumab: a comparison of infection rates across atopic dermatitis trials in adults, adolescents, children and infants	16
DP02 (P30) Declining staff numbers and increasing workload: is there a solution?	16
343 Dupilumab efficacy on itch and skin lesions in adult patients with prurigo nodularis may be observed concurrently or independently over 24 weeks: results from two phase 3 trials	16
DP22 A solitary neurofibroma masquerading as smooth muscle hamartoma: a clinicopathological challenge	16
P15 Progressive papulonodular eruption following COVID-19 infection: a rare diagnosis and review of the literature	16
DS21 Patients’ experience with one-stop skin cancer clinics	16
P45 An analysis of infantile haemangioma referrals and comparison with the infantile haemangioma European task force’s ‘infantile haemangioma referral score’	16
P046 Investigating sexual side-effects in female patients on isotretinoin via routine screening questionnaires	15
P156 Neoadjuvant immunotherapy for advanced melanoma: a clinical audit of pathological response and toxicity	15
DE02 Honing in on clinician needs: a grassroots development of an educational resource for dermatologists	15
622 - Shifting the care paradigm for individuals with skin of color (SOC): a comprehensive review of care gaps and emerging initiatives in dermatology	15
Foreword	15
P53 Incidence of merkel cell carcinoma in the Republic of Ireland (1994–2019)	15
428 Evaluating chronic pruritus prevalence, characteristics and effects on atopic dermatitis patients from a referral university hospital in São Paulo, Brazil: a cross-sectional study	15
Diverse approaches to the diagnosis and treatment of paediatric vitiligo: a survey of paediatric dermatologists	15
703 - Efficacy and safety of ruxolitinib cream in children aged 2 to 11 years with moderate and/or more extensive atopic dermatitis: subgroup analysis from the TRuE-AD3 study	15
Officers and Committee 2024–2025	15
A study looking at a possible new drug, HB0017, for the treatment of psoriasis	15
BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata	15
O11 A patchy prognosis: identification of prognostic factors associated with progression in early-stage mycosis fungoides and first-line treatment selection	15
HX22 Shining a light on dermatology	15
BI30 Remission of a large plantar verruca vulgaris in an immunocompromised patient postincisional punch biopsy	15
FC09 Clinical and immunomodulatory effects of mesenchymal stromal cells in multiple biologic-refractory psoriasis	15
696 - Sustained improvements over 140 weeks in signs, symptoms, and quality of life with upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis: integrated results from the p	15
BH21 Segmented heterochromia with calibre change: an under-recognized sign of alopecia areata	15
BH14 Multiple sclerosis and alopecia areata: drug-induced alopecia areata or coexisting autoimmune phenomena?	15
A global study of 17 009 women reveals significant skin condition changes associated with irregular menstrual cycles	14
The importance of accurate epidemiological data of epidermolysis bullosa	14
Stigma in vitiligo: associated factors and severity strata of the Patient Unique Stigmatization Holistic tool in Dermatology (PUSH-D) score	14
The association between atopic dermatitis and acne: a retrospective Finnish nationwide registry study	14
Immunoregulatory effects of TPM203 peptide-nanoparticle therapy in pemphigus vulgaris	14
Dermatitis cruris pustulosa et atrophicans	14
Nicotinamide for skin cancer chemoprevention in transplant recipients: a critically appraised topic	14
Promising results for treatment of severe chronic hand eczema with dupilumab	14
Haematohidrosis	14
Guselkumab for hidradenitis suppurativa: a phase II, open-label, mode-of-action study	14
More than skin deep: a survey of real-life experiences of acne vulgaris	14